Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Neonatol ; 64(2): 160-167, 2023 03.
Article in English | MEDLINE | ID: mdl-36224067

ABSTRACT

BACKGROUND: The role of prematurity and pulmonary inflammation in the pathogenesis of bronchopulmonary dysplasia (BPD) is very well-defined. However, there is limited knowledge about whether the level of prematurity and surfactant therapy alter the pulmonary cytokines and endothelial growth factor (VEGF). METHODS: This study analyzed the VEGF and cytokines, including interleukin (IL)-1ß, IL-6, IL-8, and IL-10, and tumor necrosis factor α (TNF-α) in the tracheal aspirate (TA) of preterm infants obtained before (within 2 h after birth) and 10-12 h after the administration of the first dose of surfactant. TA was collected from 40 infants of 35 or fewer weeks of gestation, including extremely (Group 1, n = 19), very (Group 2, n = 13), and moderate/late (Group 2, n = 8) preterm neonates. In addition to univariate analysis, controlled regression models estimated the association of perinatal factors with the tested parameters and their role in the development of BPD. RESULT: We recorded significantly lower post-partum levels of VEGF and higher IL-8, IL-1ß, and TNF-α in the TA of Group 1 infants than in Group 2 and 3. Compared to the infants in Group 2 and 3, the post-surfactant increases of pulmonary VEGF, IL-8, IL-10, and TNF-α were more significant in Group 1. All tested parameters in Group 1 and 2 infants, before and after surfactant administration, were comparable. BPD was recorded in nearly 60% of the extremely preterm survivors and was significantly predicted by increased IL-8 before, and elevated TNF-α level after surfactant administration. CONCLUSION: This study indicates the association of birth at extremely preterm gestation with reduction in pulmonary VEGF and exacerbation of pro-inflammatory cytokines followed by greater elevation post-surfactant administration levels of VEGF, IL-8, TNF-α, and IL-10 than in neonates born with gestational age of 28-35 weeks.


Subject(s)
Bronchopulmonary Dysplasia , Pneumonia , Pulmonary Surfactants , Infant , Pregnancy , Female , Infant, Newborn , Humans , Infant, Premature/metabolism , Interleukin-10 , Inflammation Mediators/metabolism , Tumor Necrosis Factor-alpha , Surface-Active Agents , Interleukin-8 , Vascular Endothelial Growth Factor A , Cytokines , Pulmonary Surfactants/therapeutic use , Bronchopulmonary Dysplasia/etiology
SELECTION OF CITATIONS
SEARCH DETAIL